GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syntara Ltd (FRA:UUDA) » Definitions » Gross-Profit-to-Asset %

Syntara (FRA:UUDA) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Syntara Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Syntara's annualized Gross Profit for the quarter that ended in Dec. 2024 was €0.00 Mil. Syntara's average Total Assets over the quarter that ended in Dec. 2024 was €9.69 Mil. Therefore, Syntara's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 0.00%.


Syntara Gross-Profit-to-Asset % Historical Data

The historical data trend for Syntara's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syntara Gross-Profit-to-Asset % Chart

Syntara Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.84 17.05 23.32 11.45 -

Syntara Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.01 19.85 - - -

Competitive Comparison of Syntara's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Syntara's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syntara's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Syntara's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Syntara's Gross-Profit-to-Asset % falls into.


;
;

Syntara Gross-Profit-to-Asset % Calculation

Syntara's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Jun. 2024 )/( (Total Assets (A: Jun. 2023 )+Total Assets (A: Jun. 2024 ))/ count )
=0/( (14.883+6.404)/ 2 )
=0/10.6435
=0.00 %

Syntara's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=0/( (6.404+12.97)/ 2 )
=0/9.687
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Syntara Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Syntara's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Syntara Business Description

Traded in Other Exchanges
Address
20 Rodborough Road, Unit 2, Frenchs Forest, Sydney, NSW, AUS, 2086
Syntara Ltd is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. It is targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company has various drug candidates in its pipeline such as SNT-5505, SNT-4728, SNT-5382, and SNT-8370 as a potential treatment for cancer, skin scarring, and neuroinflammation.

Syntara Headlines

No Headlines